Results showed that treatment often didnt follow a linear path
M Asif et al., "Incidence of Glaucoma in Type 2 Diabetes Patients Treated With GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis," Endocrinol Diabetes Metab., 8:e70059 (2025)
Growing consumer awareness of obesity health risks and treatment options is driving increased consultation rates with endocrinology specialists
Several research teams are investigating this potential effect, but robust controlled data do not yet exist to confirm semaglutide's efficacy for reducing alcohol consumption in the general population
(A reminder: GLP-1s were developed originally to help regulate blood sugar for people with diabetes, and then started to get prescribed off-label because of their weight loss effects.) It's not just weight loss, though
Marketed under the brand names Mounjaro (for diabetes) and Zepbound (for weight management), tirzepatide represents a significant advancement in metabolic disease therapy
